New implantable 'Cell Pouch' could free diabetics from insulin shots
NCT ID NCT03513939
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a device called the Cell Pouch, which is implanted in the abdomen to create a natural home for donor insulin-producing cells. The goal is to help people with type 1 diabetes who have dangerous low blood sugar episodes. Seventeen participants will receive the implant and donor islet cells while taking immunosuppressive drugs to prevent rejection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sernova Cell Pouch (implantable device) with donor islet cells
What this could lead to
If it works, this could provide a new way to transplant insulin-producing cells into the body, potentially reducing or eliminating the need for insulin injections in people with type 1 diabetes.
What could go wrong
This is an early Phase 1/2 trial with only 17 participants, so results may not apply to everyone. The procedure requires lifelong immunosuppression, which carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States